Brazil Human Insulin Drugs Market Size 2024-2028
Brazil - human insulin drugs market size is estimated to grow by USD 181.76 million at a CAGR of 6.5% between 2023 and 2028.
There has been a notable increase in understanding among healthcare professionals and the general population regarding the crucial role that insulin plays in effectively managing diabetes. This heightened awareness has translated into improved diagnosis rates and greater emphasis on the importance of insulin in the overall treatment regimen. Furthermore, initiatives aimed at educating the public, healthcare professionals, and even policymakers about the significance of insulin therapy have played a pivotal role. These efforts have not only increased awareness but have also addressed misconceptions surrounding insulin, fostering a more positive perception of its role in diabetes care. Consequently, individuals are more likely to seek and adhere to insulin therapy, thereby driving market growth during the forecast period. It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
What will be the size of the Brazil Human Insulin Drugs Market During the Forecast Period?
To learn more about this report, Download Report Sample
Market Segmentation
The Brazil human insulin drugs market report forecasts market growth by revenue and provides an analysis of the latest market growth and trends opportunities from 2018 to 2028.
- Product Outlook
- Basal insulin analog
- NPH (Neutral Protamine Hagedorn)
- Application Outlook
- Type I diabetes
- Type II diabetes
- Distribution Channel Outlook
- Retail
- Hospitals
Product Analysis
The market share growth by the basal insulin analog segment will be significant during the forecast period. Basal analogs form a crucial part of insulin replacement therapy, in which these drugs are used to maintain a basal secretion (~50%), which means a constant concentration of insulin needed to maintain a normal blood glucose level and a prandial secretion (~50%), which means normalizing the blood glucose level following a meal. The segment is witnessing growth due to the improved therapeutic outcomes associated with basal insulin analogs
Get a glance at the market contribution of various segments Download PDF Sample
The basal insulin analog segment was valued at USD 262.13 million in 2018. Basal analogs have a longer duration of action, fewer variations, more predictable therapeutic outcomes, and less hypoglycemia (especially during the night). Detemir has a more favorable weight profile also. Consequently, lesser dosing administration or lesser injection of basal analogs is required for basal analogs when compared to NPH. Furthermore, clinical trials have demonstrated that a decreased incidence of weight gain and hypoglycemia is observed when treated with basal analogs. Thus, the demand for basal analogs for the treatment of diabetes is expected to increase in Brazil, thereby driving the growth of the Brazil - human insulin drugs market during the forecast period.
Application Analysis
Type I diabetes
Despite the low prevalence of type I diabetes, this segment held the largest revenue share of the Brazil - human insulin drugs market, due to the high dependence of type I diabetes patients on human insulin drugs. Furthermore, the presence of large vendors, such as Novo Nordisk AS, Eli Lilly and Co., and Sanofi SA, that are offering branded and generic versions of highly effective human insulin drugs are contributing to the growth of the market. Moreover, the disease usually develops at a very young age, thus increasing the duration of treatment with human insulin drugs. Due to such factors, this segment of the market is expected to grow during the forecast period.
Type II diabetes
Type II diabetes is a condition in which the pancreas produces insulin, unlike in type I diabetes, but the cells cannot utilize this insulin for regulating the glucose concentration in the blood, leading to increased blood sugar levels. Furthermore, the use of non-pharmacotherapy for the management of type II diabetes inhibits the rationale of the use of human insulin drugs, which is a main challenge for the growth of this segment. Despite the limited scope of the use of human insulin drugs for the treatment of type II diabetes, the growing geriatric population will drive segment growth of the market during the forecast period.
Key Brazil Human Insulin Drugs Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 13 market companies, including:
Becton Dickinson and Co.: The company offers human insulin drugs such as Insulin Delivery Devices which includes BD Micro Fine Plus Pen Needles, BD Micro Fine Plus Insulin Syringes, and BD SafetyGlide Safety Insulin Syringes.
- Biocon Ltd.
- Biomm
- Eli Lilly and Co.
- Empreendimentos Pague Menos SA
- Gulf Pharmaceutical Industries
- MannKind Corp.
- Medtronic Plc
- Merck and Co. Inc.
- Novartis AG
- Novo Nordisk AS
- Sanofi SA
- Wockhardt Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Brazil Human Insulin Drugs Market Dynamics and Customer Landscape
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Key Brazil Human Insulin Drugs Market Drivers
Demographic transition in Brazil is the key factor driving market growth. Brazil has been undergoing a transition in terms of the epidemiology of non-communicable diseases. In the country, non-communicable diseases have supplanted communicable diseases, and they are identified as one of the leading causes of mortality and morbidity. Since type I diabetes affects an individual at a very young age, the presence of a young population base provides an opportunity for players to enter the Brazil - human insulin drugs market.
Furthermore, all Latin American countries, including Brazil, have undergone rapid demographic, nutritional, and epidemiological transitions, which have strongly led to an increase in the prevalence of diabetes in this region. Thus, as per the market forecast based on these factors, it is expected to have a positive impact on the market. The increasing prevalence of diabetes is expected to augment the growth of the market during the forecast period.
Key Brazil Human Insulin Drugs Market Trends
Increasing initiatives by companies is the primary trend shaping market growth. The Brazil - human insulin drugs market is currently witnessing a rise in the efforts of companies to increase the accessibility and affordability of human insulin drugs. For example, Eli Lilly and Co.s diabetes solution center supports patients who are unable to afford the medical expenses associated with the insulin drugs by Eli Lilly and Co., such as those with a low disposable income, those who are not insured, or people who are in a deductible phase of a high-deductible insurance plan.
Moreover, the company also pays rebates and other discounts, which can be attributed to factors such as high market competition, rising mandatory government discounts, and pharmacy benefit managers increased negotiation leverage. Therefore, such market trends and analysis based on these factors forecast a positive impact on the market. Furthermore, certain changes in insurance plans and the trend of high consumer cost-sharing through high-deductible plans and co-insurance indicate that the patients are exposed to the full retail price at pharmacies, which will drive market growth during the forecast period.
Key Brazil Human Insulin Drugs Market Challenges
The high cost of human insulin drugs is a challenge that affects market growth. With the rising prevalence of diabetes and hypertension in Brazil since 2005, the financial burden associated with the treatment of these conditions has increased manifold. In Brazil, more than 25% of the population lives with half of their minimum wages per month, of which 10% of the population lives with one-fourth of their wages, and less than 5% of the population lives in extreme poverty, with spending up to one dollar per day. Thus, the high cost associated with human insulin drugs reduces patient adherence to these drugs in the country.
Furthermore, it is estimated that the geriatric population in Brazil, which includes retirees and pensioners, spends more than 50% of their wages on purchasing medicines. This indicates that a patient with type I diabetes, who would require life-long treatment with human insulin drugs, can find it difficult to afford the treatment due to his/her low disposable income. Therefore, as per the Market forecasting analysis based on these factors, it is expected to have a negative impact on the market. it is expected to have a positive impact on the market. Thus, the high cost of human insulin drugs is expected to impede the growth of the market during the forecast period.
Market Customer Landscape
The market growth and forecasting analysis report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. The market analysis and report focus on adoption rates in different regions based on penetration. Furthermore, the market research and growth report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Brazil Human Insulin Drugs Market Customer Landscape
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
142 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.5% |
|
Market Growth 2024-2028 |
USD 181.76 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.4% |
|
Key countries |
US, China, Japan, UK, and Germany |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Barista Coffee, Brew Berrys Hospitality Pvt Ltd., Caffe Nero Group Ltd, Caribou Coffee Operating Co. Inc., Costa Ltd., Inspire Brands Inc., Luckin Coffee Inc., McDonald Corp., MTY Food Group Inc., Nestle SA, Peets Coffee Inc., Starbucks Corp., Coffee Beanery, Coffee Day Enterprises Ltd., Doutor Coffee Co. Ltd., EDIYA COFEE CO., Grupo Herdez, La Colombe Coffee Roasters., PILOT COFFEE ROASTERS, and Blue Tokai Coffee |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
- Precise estimation of the size of the market and its contribution of the market in focus to the parent market
- Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
- Growth of the market across Brazil
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch